SNORA14A: A Small Nucleolar RNA with Promising Potential as a Drug Target

Target Name: SNORA14A

NCBI ID: G677801

SNORA14A

Other Name(s): small nucleolar RNA, H/ACA box 14A | ACA14a | Small nucleolar RNA, H/ACA box 14A

SNORA14A: A Small Nucleolar RNA with Promising Potential as a Drug Target

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the well-known snRNAs is H/ACA box 14A (SNORA14A), which is expressed in high levels in various tissues and cell types. Its function and potential as a drug target have been the focus of intense research in recent years.

SNORA14A is a 24.1 kilobase (kb) RNA molecule that is located within the H/ACA box 14A gene in the 5'-end of the nucleus. The H/ACA box is a conserved region that is present in many snRNAs and is involved in the recognition of specific DNA sequences. The A region of SNORA14A contains a unique open reading frame that is specific to this RNA molecule.

Functional characterization of SNORA14A has shown that it plays a critical role in the regulation of gene expression in various cell types. For example, studies have shown that SNORA14A is highly expressed in the human placenta, and its levels are regulated by various factors, including microbiome RNA (miRNA) pathways, RNA binding proteins (RBP), etc. Furthermore, SNORA14A has also been shown to play a role in the regulation of stem cell self-renewal and the association with cancer.

SNORA14A has also been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key reasons for its potential as a drug target is its high expression levels, which make it an attractive target for small molecule inhibitors. Additionally, the unique structure of SNORA14A has allowed researchers to identify new targets for drug development, such as small molecules that can interact with specific regions of the RNA molecule.

In recent years, various studies have investigated the potential drug targets of SNORA14A. One of the most promising strategies is the use of small molecules to inhibit the activity of SNORA14A. Studies have shown that various small molecules, such as inhibitors of RNA binding proteins, can inhibit the activity of SNORA14A and decrease its levels in various cell types.

Another approach to identify potential drug targets of SNORA14A is the use of RNA interference (RNAi) technology. RNAi is a technique that involves the introduction of small interfering RNA (siRNA) into cells to knockdown gene expression. By using RNAi to knockdown the levels of SNORA14A, researchers have been able to determine its role in various cellular processes and identify potential drug targets.

In addition to its potential as a drug target, SNORA14A also has several potential applications as a biomarker. Its high expression levels make it an attractive target for diagnostic tools, such as qRT-PCR, RNAseq, and microarray analysis. Additionally, the unique structure of SNORA14A has allowed researchers to develop new biomarkers that can be used to monitor the expression of specific genes.

In conclusion, SNORA14A is a small nucleolar RNA that has been shown to play a critical role in the regulation of gene expression in various cell types. Its unique structure and high expression levels make it an attractive target for small molecule inhibitors and RNAi technology. Additionally , its potential as a drug target and biomarker make it an exciting area of 鈥嬧?媟esearch for the future.

Protein Name: Small Nucleolar RNA, H/ACA Box 14A

The "SNORA14A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA14A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets